26th October 2022
Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment
The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.
25th October 2022
Striving for more: personalizing care in patients with psoriatic disease
Striving for more: personalizing care in palients with psoriatic disease. Educational objectives: Understand what patients need and expect from their treatment journey from its outset. Drive the importance of collecting patient reported outcomes on registries and analysing data by gender/age. Consider shared decision-making as essential throughout a patient’s joumey, understanding how it can further treatment personalisation and patient outcomes
13th October 2022
Current challenges and future perspectives in Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis
As part of Novartis’ continued commitment to medical education in rheumatology. We Invite you to our faculty as they discuss: -The disease state of JPsA and ERA and the impact of diagnosis, clinical features, and disease activity on patients and caregivers. -The importance of both the patient perspective and the unmet needs for optimizing the management of JPsA and ERA -Clinical evidence for IL17 inhibition in the management of ERA and JPsA.
12th October 2022
Channelling the myotonia diagnosis: ICNMD symposium presentations
Watch full presentations given by Prof. Dr Kristl Claeys, Dr Guillaume Bassez and Prof. John Vissing at the Lupin-sponsored symposium at the 17th International Congress on Neuromuscular Diseases, in July 2022, in Brussels, Belgium.
22nd September 2022
Changing Practices and the Impact of New Treatments in Multidisciplinary Cancer Care
A multidisciplinary team (MDT) approach is considered the gold standard for the diagnosis and treatment of cancer. The objectives of this webinar are to: Summarise key changes in MDT practice in the past and the lessons learned and benefits derived from these changes